ADVERTISEMENT
Biocon's Woes: Why Cracking Biosimilars Will Be A Challenge For Indian Drugmakers
Are biosimilars as attractive as they are touted to be for Indian durgmakers?
10 Nov 2021, 11:06 AM IST
Biocon Ltd., India's largest biopharma company, bet on gaining a large share of the biosimilars market in the U.S. as generics started facing competition and pricing pressure. A decade later, it has run into a similar bump. And that underscores the challenge its Indian peers will also face in a growing segment of the market. Biosimilars are near-identical copies of an original, approved biological medicine and are often manufactured ...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Free
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT